Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Pfizer (PFE) PT Raised to $30 at Citi
August 13, 2024 4:41 PM EDTCiti analyst Andrew Baum raised the price target on Pfizer (NYSE: PFE) to $30.00 (from $28.00) while maintaining a Neutral rating.
The analyst comments "We update our forecasts post 2Q24 to incorporate latest results and guidance, and sales, prescription, and currency trends. Our 2024E non-GAAP EPS... More
